

17 April 2023

Scancell Holdings plc
("Scancell" or the "Company")

Block Listing Application to AIM

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies, announces an application has been made to AIM for a block listing of 2,880,000 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares"). This will be used to facilitate the admission of Ordinary Shares to trading following the exercise of options granted on the basis of one share per share option.

The Ordinary Shares will be issued from time to time pursuant to the Company's existing share options plan for Richard Goodfellow for outstanding options already issued but not yet exercised by Richard Goodfellow. New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank *pari passu* in all respects with the existing Ordinary Shares.

The block listing is expected to become effective on 20 April 2023. The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.

At the time of this announcement, Scancell has 818,403,461 Ordinary Shares in issue. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Scancell Holdings plc	+44 (0) 20 3727 1000
Dr Jean-Michel Cosséry, Non-Executive Chairman	+44 (0) 20 7886 2500
Professor Lindy Durrant, CEO	
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)	+44 (0) 20 7710 7600
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)	
Nick Adams/Nick Harland (Corporate Broking)	
Panmure Gordon (UK) Limited (Joint Broker)	+44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)	
Rupert Dearden (Corporate Broking)	
FTI Consulting	+44 (0) 20 3727 1000
Simon Conway/Rob Winder/Alex Davis	

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope[®] and ImmunoBody[®] for vaccines and GlyMab[®] and AvidiMab[®] for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope[®] and ImmunoBody[®]) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab[®]) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab[®]).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>